vs
博思艾伦汉密尔顿（BAH）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
博思艾伦汉密尔顿的季度营收约是瑞思迈的1.8倍（$2.6B vs $1.4B），瑞思迈净利率更高（27.6% vs 7.6%，领先20.0%），瑞思迈同比增速更快（11.0% vs -10.2%），瑞思迈自由现金流更多（$311.2M vs $248.0M），过去两年瑞思迈的营收复合增速更高（9.0% vs -2.8%）
博思艾伦汉密尔顿控股集团是美国知名专业服务企业，深耕数字化转型与人工智能领域，为公共部门、私营机构及非营利组织提供咨询、分析与工程服务，总部位于弗吉尼亚州麦克莱恩，属华盛顿大都会区，在全球另设有80个办事处。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
BAH vs RMD — 直观对比
营收规模更大
BAH
是对方的1.8倍
$1.4B
营收增速更快
RMD
高出21.2%
-10.2%
净利率更高
RMD
高出20.0%
7.6%
自由现金流更多
RMD
多$63.2M
$248.0M
两年增速更快
RMD
近两年复合增速
-2.8%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.6B | $1.4B |
| 净利润 | $200.0M | $392.6M |
| 毛利率 | 51.9% | 61.8% |
| 营业利润率 | 8.8% | 34.6% |
| 净利率 | 7.6% | 27.6% |
| 营收同比 | -10.2% | 11.0% |
| 净利润同比 | 7.0% | 13.9% |
| 每股收益（稀释后） | $1.63 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAHRMD
| Q4 25 | $2.6B | $1.4B | ||
| Q3 25 | $2.9B | $1.3B | ||
| Q2 25 | $2.9B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $2.9B | $1.3B | ||
| Q3 24 | $3.1B | $1.2B | ||
| Q2 24 | $2.9B | $1.2B | ||
| Q1 24 | $2.8B | $1.2B |
净利润BAHRMD
| Q4 25 | $200.0M | $392.6M | ||
| Q3 25 | $175.0M | $348.5M | ||
| Q2 25 | $271.0M | $379.7M | ||
| Q1 25 | $192.7M | $365.0M | ||
| Q4 24 | $186.9M | $344.6M | ||
| Q3 24 | $390.1M | $311.4M | ||
| Q2 24 | $165.2M | $292.2M | ||
| Q1 24 | $128.0M | $300.5M |
毛利率BAHRMD
| Q4 25 | 51.9% | 61.8% | ||
| Q3 25 | 53.6% | 61.5% | ||
| Q2 25 | 51.3% | 60.8% | ||
| Q1 25 | 53.6% | 59.3% | ||
| Q4 24 | 55.2% | 58.6% | ||
| Q3 24 | 56.7% | 58.6% | ||
| Q2 24 | 53.4% | 58.5% | ||
| Q1 24 | 54.7% | 57.9% |
营业利润率BAHRMD
| Q4 25 | 8.8% | 34.6% | ||
| Q3 25 | 9.8% | 33.4% | ||
| Q2 25 | 8.8% | 33.7% | ||
| Q1 25 | 9.2% | 33.0% | ||
| Q4 24 | 10.0% | 32.5% | ||
| Q3 24 | 17.4% | 31.6% | ||
| Q2 24 | 8.7% | 31.2% | ||
| Q1 24 | 9.5% | 31.3% |
净利率BAHRMD
| Q4 25 | 7.6% | 27.6% | ||
| Q3 25 | 6.1% | 26.1% | ||
| Q2 25 | 9.3% | 28.2% | ||
| Q1 25 | 6.5% | 28.3% | ||
| Q4 24 | 6.4% | 26.9% | ||
| Q3 24 | 12.4% | 25.4% | ||
| Q2 24 | 5.6% | 23.9% | ||
| Q1 24 | 4.6% | 25.1% |
每股收益（稀释后）BAHRMD
| Q4 25 | $1.63 | $2.68 | ||
| Q3 25 | $1.42 | $2.37 | ||
| Q2 25 | $2.16 | $2.58 | ||
| Q1 25 | $1.52 | $2.48 | ||
| Q4 24 | $1.45 | $2.34 | ||
| Q3 24 | $3.01 | $2.11 | ||
| Q2 24 | $1.27 | $1.97 | ||
| Q1 24 | $0.97 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $882.0M | $1.4B |
| 总债务越低越好 | $3.9B | $403.9M |
| 股东权益账面价值 | $1.0B | $6.3B |
| 总资产 | $7.1B | $8.5B |
| 负债/权益比越低杠杆越低 | 3.84× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资BAHRMD
| Q4 25 | $882.0M | $1.4B | ||
| Q3 25 | $816.0M | $1.4B | ||
| Q2 25 | $711.0M | $1.2B | ||
| Q1 25 | $885.0M | $932.7M | ||
| Q4 24 | $453.5M | $521.9M | ||
| Q3 24 | $558.7M | $426.4M | ||
| Q2 24 | $297.7M | $238.4M | ||
| Q1 24 | $554.3M | $237.9M |
总债务BAHRMD
| Q4 25 | $3.9B | $403.9M | ||
| Q3 25 | $4.0B | $408.7M | ||
| Q2 25 | $4.0B | $658.4M | ||
| Q1 25 | $4.0B | $663.1M | ||
| Q4 24 | $3.4B | $662.9M | ||
| Q3 24 | $3.4B | $667.6M | ||
| Q2 24 | $3.4B | $697.3M | ||
| Q1 24 | $3.4B | $997.0M |
股东权益BAHRMD
| Q4 25 | $1.0B | $6.3B | ||
| Q3 25 | $996.0M | $6.1B | ||
| Q2 25 | $1.1B | $6.0B | ||
| Q1 25 | $1.0B | $5.5B | ||
| Q4 24 | $1.2B | $5.3B | ||
| Q3 24 | $1.2B | $5.2B | ||
| Q2 24 | $1.1B | $4.9B | ||
| Q1 24 | $1.0B | $4.6B |
总资产BAHRMD
| Q4 25 | $7.1B | $8.5B | ||
| Q3 25 | $7.2B | $8.3B | ||
| Q2 25 | $7.2B | $8.2B | ||
| Q1 25 | $7.3B | $7.6B | ||
| Q4 24 | $6.8B | $7.1B | ||
| Q3 24 | $6.9B | $7.2B | ||
| Q2 24 | $6.6B | $6.9B | ||
| Q1 24 | $6.6B | $6.8B |
负债/权益比BAHRMD
| Q4 25 | 3.84× | 0.06× | ||
| Q3 25 | 3.98× | 0.07× | ||
| Q2 25 | 3.74× | 0.11× | ||
| Q1 25 | 3.99× | 0.12× | ||
| Q4 24 | 2.79× | 0.13× | ||
| Q3 24 | 2.83× | 0.13× | ||
| Q2 24 | 3.14× | 0.14× | ||
| Q1 24 | 3.26× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $261.0M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $248.0M | $311.2M |
| 自由现金流率自由现金流/营收 | 9.5% | 21.9% |
| 资本支出强度资本支出/营收 | 0.5% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.30× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $933.4M | $1.8B |
8季度趋势，按日历期对齐
经营现金流BAHRMD
| Q4 25 | $261.0M | $339.7M | ||
| Q3 25 | $421.0M | $457.3M | ||
| Q2 25 | $119.0M | $538.8M | ||
| Q1 25 | $219.0M | $578.7M | ||
| Q4 24 | $150.8M | $308.6M | ||
| Q3 24 | $587.1M | $325.5M | ||
| Q2 24 | $52.1M | $440.1M | ||
| Q1 24 | $143.8M | $402.0M |
自由现金流BAHRMD
| Q4 25 | $248.0M | $311.2M | ||
| Q3 25 | $395.0M | $414.4M | ||
| Q2 25 | $96.0M | $508.2M | ||
| Q1 25 | $194.4M | $557.9M | ||
| Q4 24 | $133.6M | $288.0M | ||
| Q3 24 | $563.3M | $307.7M | ||
| Q2 24 | $19.7M | $415.2M | ||
| Q1 24 | $127.6M | $380.8M |
自由现金流率BAHRMD
| Q4 25 | 9.5% | 21.9% | ||
| Q3 25 | 13.7% | 31.0% | ||
| Q2 25 | 3.3% | 37.7% | ||
| Q1 25 | 6.5% | 43.2% | ||
| Q4 24 | 4.6% | 22.5% | ||
| Q3 24 | 17.9% | 25.1% | ||
| Q2 24 | 0.7% | 33.9% | ||
| Q1 24 | 4.6% | 31.8% |
资本支出强度BAHRMD
| Q4 25 | 0.5% | 2.0% | ||
| Q3 25 | 0.9% | 3.2% | ||
| Q2 25 | 0.8% | 2.3% | ||
| Q1 25 | 0.8% | 1.6% | ||
| Q4 24 | 0.6% | 1.6% | ||
| Q3 24 | 0.8% | 1.5% | ||
| Q2 24 | 1.1% | 2.0% | ||
| Q1 24 | 0.6% | 1.8% |
现金转化率BAHRMD
| Q4 25 | 1.30× | 0.87× | ||
| Q3 25 | 2.41× | 1.31× | ||
| Q2 25 | 0.44× | 1.42× | ||
| Q1 25 | 1.14× | 1.59× | ||
| Q4 24 | 0.81× | 0.90× | ||
| Q3 24 | 1.50× | 1.05× | ||
| Q2 24 | 0.32× | 1.51× | ||
| Q1 24 | 1.12× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAH
| Defense Clients | $1.5B | 55% |
| Civil Clients | $732.0M | 28% |
| Intelligence Clients | $434.0M | 17% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
